Compass Therapeutics to Participate in Upcoming September Investor Events

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September.

Details are as follows:

Citi’s 2025 Biopharma Back to School Conference Location: Boston, MADate: Tuesday, September 2, 2025

Cantor Global Healthcare ConferenceLocation: New York, NYDate: Wednesday, September 3, 2025Time: 2:10 PM ETWebcast Link: https://cmpx.info/cantor

H.C. Wainwright 27th Annual Global Investment ConferenceLocation: New York, NYDate: Monday, September 8, 2025Time: 11 AM ETWebcast Link: https://journey.ct.events/view/c21a88e1-14c6-46cd-85b8-dbfa550d85a1

Morgan Stanley 23rd Annual Global Healthcare ConferenceLocation: New York, NYDate: Tuesday, September 9, 2025 Time: 5:35 PM ETWebcast Link: https://cc.webcasts.com/morg007/090825a_js/?entity=89_N2MHE8Q

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Investor Contactir@compasstherapeutics.com

Media ContactAnna Gifford, Chief of Staffmedia@compasstherapeutics.com 617-500-8099